Skip to content
Screener

DBV Technologies DBVT Cash & Equivalents

Cash & Equivalents at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$85.61M+101%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$78.64M+8.0%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$110.73M+61.3%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$47.45M+106%
Alumis Inc. logo
Alumis Inc.ALMS
$63.89M-50.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNoteJune 30, 2026December 31, 2025
Assets
Current assets :
Cash and cash equivalents3174.9194.2
Other current assets527.018.8
Total current assets201.9212.9
Property, plant, and equipment, net49.710.4
Right-of-use assets65.94.6
Other non-current assets55.85.8

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's cash & equivalents?
DBV Technologies (DBVT) reported cash & equivalents of $174.9M in Q2 2026.
How has DBV Technologies's cash & equivalents changed year-over-year?
DBV Technologies's cash & equivalents increased by 69.5% year-over-year, from $103.21M to $174.9M.
What is the long-term trend for DBV Technologies's cash & equivalents?
Over 5 years (2020 to 2025), DBV Technologies's cash & equivalents has grown at a -0.2% compound annual growth rate (CAGR), from $196.35M to $194.2M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about DBV Technologies's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude